N/A N=1,196 Coordinated, Collaborative, Comprehensive, Family-based, Integrated, Technology-enabled Stroke Care
Stroke · Stroke, Ischemic · Stroke, Acute
Primary: Stroke Impact Scale (SIS) at 12-months Post-discharge — 80.42; 83.85 Score
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=20 Perinatal Stroke: Understanding Brain Reorganization
Stroke · Hemiparesis
Primary: Cortical Excitability MEP Amplitude (µV) — 325 µV
N/A N=5 TOlerability of Transcranial Direct Current Stimulation in Pediatric Stroke Survivors
Childhood Stroke
Primary: Number of Participants Who Complete the Study — 5 Participants
Phase 1 N=24 A Phase Ib/II in Patients With Acute Ischemic Stroke
Ischemic Stroke
Primary: Maximum Tolerated Dose (MTD) of DDFPe Evaluated by Number of Dose Limiting Toxicities — 0; 0; 0; 0 Dose Limiting Toxicities
N/A N=16 American Heart Association- Stroke/Hypoxia Study
Stroke
Primary: Number of Participants With Adverse Events — 1; 11; 2; 10 Participants
N/A N=1,509 Stroke Ready - Optimizing Acute Stroke Care
Stroke, Acute · Stroke
Primary: Utilization of Thrombolysis Among Ischemic Stroke and Transient Ischemic Attack (TIA) Patients — 4; 14 Percent of stroke and TIA patients
N/A N=20 Brain Stimulation and Hand Training in Children With Hemiparesis
Pediatric Hemiparesis
Primary: Change in Assisting Hand Assessment (AHA) — 6.4; 8; 5.5; 7.6 score on a scale
N/A N=129 Stroke Ready: A Stroke Preparedness Brief Intervention
Stroke
Primary: Change in Behavioral Intent to Call 911 — 2.1; 0.4 units on a scale
N/A N=10 Synchronized Brain and Hand Stimulation After Stroke
Stroke · Upper Extremity Paresis
Primary: Percent Change in Box and Block Test — 20 percent change of number of blocks — p=.04
N/A N=25 Measurement of Cerebral Blood Flow Using Transcranial Doppler Ultrasound in Children With Sickle Cell Disease
Sickle Cell Disease
Primary: Measurement of Time Average Mean of the Maximum (TAMM) in cm/Sec in Cerebral Arteries Using 2 Different Ultrasound Machines. — 120; 120 cm/sec
Phase 2 N=79 Study of Allogeneic Umbilical Cord Blood Infusion for Adults With Ischemic Stroke
Stroke · Stroke, Acute · Brain Injury, Acute
Primary: Shift in Modified Rankin Scale (mRS) — 1; 1 score on a scale — p=0.71
Phase 3 N=196 Silent Cerebral Infarct Transfusion Multi-Center Clinical Trial
Sickle Cell Anemia · Stroke
Primary: Recurrence of an Infarct, Defined as a Stroke or a New or Enlarged Silent Cerebral Infarct — 2.0; 4.8 infarct recurrence per 100 person years
Phase 2 N=24 Improving Stroke Rehabilitation: Spacing Effect and D-cycloserine
Stroke
Primary: Wolf Motor Function Test (Time) — 10.21; 29.69; 19.09; 26.05 units on a scale — p=<0.05
N/A N=140 Reducing Risk of Recurrence
Stroke · TIA · Hypertension
Primary: Systolic Blood Pressure — 130.83; 133.67 mm Hg — p=0.29
Phase 1 N=11 Aspirin Prophylaxis in Sickle Cell Disease
Sickle Cell Disease
Primary: Number of Serious Adverse Events — 6; 9; 0; 0 events
N/A N=20 Heart-Brain Retraining for Stroke Rehabilitation
Stroke
Primary: Wolf Motor Function Test (WMFT) — 45.17; 49.75; 59.83; 49.80 units on a scale
N/A N=4 Novel Brain Signal Feedback Paradigm to Enhance Motor Learning After Stroke
Stroke
Primary: Arm Motor Abilities Test Functional Domain (AMAT - F) — .54 units on a scale
Phase 4 N=469 Learning Impairments Among Survivors of Childhood Cancer
Acute Lymphoblastic Leukemia · Brain Tumors
Primary: Brain White Matter Volume for Patients Versus Sibling Controls — 27; 30.3 percentage — p=<.0001
N/A N=185 A Novel Transition Program to Reduce Disability After Stroke
Ischemic Stroke · Hemorrhagic Stroke
Primary: Reintegration to Normal Living Index (RNLI) — 60.8; 61.2; 74.8; 73.9 score on a scale — p=0.76
N/A N=10 Pediatric Teleneuromodulation
Cerebral Palsy (CP)
Primary: Status/Safety Assessment — 4; 7; 20; 12 number of sessions symptom reported
N/A N=22 Combined Brain and Peripheral Nerve Stimulation for Stroke
Stroke
Primary: Active Range of Motion of Wrist Extension in the Paretic Side — 37.8; 38; 37.2; 38 degrees
Phase 2 N=12 Hydroxyurea to Prevent Brain Injury in Sickle Cell Disease
Sickle Cell Disease · Stroke
Primary: Number of Randomized Participants With Central Nervous System Complications — 1; 4 Participants — p=0.2914
N/A N=34 Cerebral Blood Flow and Childhood Obstructive Sleep Apnea
Obstructive Sleep Apnea Syndrome
Primary: Change in Cerebral Blood Flow (CBF) at Baseline Between Obstructive Sleep Apnea Syndrome (OSAS) and Controls — 184; 209 percentage of change from baseline
Phase 2 N=18 Positional Therapy After Stroke
Sleep Apnea · Stroke
Primary: Apnea-hypopnea Index — 27; 39 events/hr — p=0.011
N/A N=14 Targeted High-definition Transcranial Direct Current Stimulation (HD-tDCS) for Reducing Post-stroke Movement Impairments
Stroke
Primary: Fugl-Meyer Upper Extremity Assessment Part A — 4.13; 5.38; 0.88 score on a scale — p=<0.0001
N/A N=103 Patient Targeted Upper Extremity Rehabilitation After Stroke
Stroke
Primary: Fugl-Meyer Assessment of the Upper Extremity — 4.08; 2.45 score on a scale — p=0.912
Phase 2 N=27 Statin Therapy in Young Adult Survivors of Childhood Cancer
Cardiovascular Disease · Childhood ALL · Childhood NHL
Primary: Change From Baseline in Brachial Artery Flow-Mediated Dilation at 6-months — -0.5; -3.4 percentage change
Early Phase 1 N=11 Safety of Transcranial Direct Current Stimulation in Pediatric Hemiparesis
Hemiparesis
Primary: Adverse Events/Safety Assessment. — 0; 0; 0; 0 Participants
N/A N=40 Learning in Stroke
Stroke · Sensorimotor Impairment
Primary: Learning Rate as Indexed by Change in the Precision of Visuomotor Grip Force Adjustment (i.e., Reduction of Precision Error in Force Adjustment) — -1.48; 0.303…
N/A N=600 Prevent Return of Stroke Study
Stroke Recurrence · Transient Ischemic Attack
Primary: Blood Pressure — 76; 65 percentage of participants